Differential expression of nitric oxide by dermal microvascular endothelial cells from patients with scleroderma

Vascular Medicine

Volumn 5, Issue 3, 2000, Pages 147-158

  Romero, L I ^a   Zhang, D N ^a   Cooke, J P ^a   Ho, H K V ^a   Avalos, E ^a   Herrera, R ^a   Herron, G S ^a  

^a Palo Alto Institute of Molecular Medicine   (United States)

Author keywords

Constitutive endothelial type nitric oxide synthase; Human dermal microvascular endothelial cells; Localized scleroderma; Systemic scleroderma

Indexed keywords

CD31 ANTIGEN; MESSENGER RNA; MONOCLONAL ANTIBODY; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

ADULT; AGED; ANTIBODY AFFINITY; ARTICLE; CELL GROWTH; CELL STRUCTURE; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MICROVASCULATURE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; SYSTEMIC SCLEROSIS; VASCULAR ENDOTHELIUM; WESTERN BLOTTING;

EID: 0033769484     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1358836x0000500304     Document Type: Article

References (75)

1. Southwestern internal medicine conference: The many faces of scleroderma
2. Capillary alterations in scleroderma
3. Diagnostic potential of in vivo capillary microscopy in scleroderma and related disorders
4. Evidence of microvascular injury in scleroderma and systemic lupus erythematosus: Quantitative study of the microvascular bed
5. Vascular abnormalities in scleroderma
6. Raynaud's phenomenon: Its relevance to scleroderma
7. Hemodynamics in nailfold capillaries of patients with systemic scleroderma: Synchronous measurements of capillary blood pressure and red blood cell velocity
8. Elevated plasma endothelin levels in systemic sclerosis
9. Characterization of endothelin binding sites in human skin and their regulation in primary Raynaud's phenomenon and systemic sclerosis
10. Elevated plasma levels of endothelin-1 in systemic sclerosis
11. Raynaud's phenomenon
12. The vascular endothelium in scleroderma
13. Nitric oxide synthase: Role in the genesis of vascular disease
14. Regression or progression. Dependency on vascular nitric oxide
15. Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit
16. Gene therapy inhibiting neointimal vascular lesion: In vivo transfer of endothelial cell nitric oxide synthase gene
17. Study of endothelial dependent relaxation in scleroderma
18. L-Arginine therapy in Raynaud's phenomenon
19. Oral L-arginine supplementation and cutaneous vascular responses in patients with primary Raynaud's phenomenon
20. Decreased nitric oxide in the exhaled air of patients with systemic sclerosis with pulmonary hypertension
21. Nitric oxide production and inducible nitric oxide synthase expression in systemic sclerosis
22. Microvascular endothelial cell culture
23. A method for the isolation and serial propagation of keratinocytes, endothelial cells, and fibroblasts from a single punch biopsy of human skin
24. Interleukin-I induces major phenotypic changes in human skin microvascular endothelial cells
25. Immunomagnetic purification of human microvessel endothelial cells using Dynabeads coated with monoclonal antibodies to PECAM-1
26. Membrane-type matrix metalloproteinases in human dermal microvascular endothelial cells: Expression and morphogenetic correlation
27. Exnhanced endothelial adhesiveness in hypercholesterolemia is attenuated by L-arginine
28. Chemistry of nitric oxide: Biologically relevant aspects
29. Scleroderma. Clinical problems/the lungs
30. Nitric oxide inhibition induces early activation of Type 1 collagen gene in renal resistance vessels and glomeruli in transgenic mice
31. Impaired wound healing and angiogenesis in eNOS-deficient mice
32. Immunological modulation of dermal fibroblasts in scleroderma
33. Sequential dermal microvascular and perivascular changes in the development of scleroderma
34. Myofibroblasts from scleroderma skin synthesize elevated levels of collagen and tissue inhibitor of metalloproteinase (TIMP-1) with two forms of TIMP-I
35. Smooth muscle differentiation in scleroderma fibroblastic cells
36. Tissue inhibitor of metalloproteinase 1 (TIMP-1) may be an autocrine growth factor in scleroderma fibroblasts
37. Activation of tissue inhibitor of metalloproteinases-3 (TIMP-3) mRNA expression in scleroderma skin fibroblasts
38. Scleroderma fibroblast phenotype is modulated by endothelial cell co-culture
39. Animal models of systemic sclerosis
40. Increased collagen synthesis by scleroderma skin fibroblasts in vitro: A possible defect in the regulation or activation of the scleroderma fibroblast
41. Isolation and characterization of microvascular endothelial cells from the adult human dermis and from skin biopsies of patients with systemic sclerosis
42. Nitric oxide synthase expression and nitric oxide production are reduced in hypertrophic scar tissue and fibroblasts
43. Regulation of endothelial nitric oxide synthase mRNA, protein, and activity during cell growth
44. Hypoxia decreases constitutive nitric oxide synthase transcript and protein in cultured endothelial cells
45. Endothelial nitric oxide synthase: Molecular cloning and characterization of a distinct constitutive enzyme isoform
46. Molecular cloning and characterization of the constitutive bovine aortic endothelial cell nitric oxide synthase
47. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life
48. Molecular regulation of the bovine endothelial cell nitric oxide synthase by transforming growth factor-beta 1
49. Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene
50. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells
51. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia
52. Nitric oxide synthase: Expression and expressional control of the three isoforms
53. Molecular biology of nitric oxide synthase
54. Neuropeptides induce release of nitric oxide from human dermal microvascular endothelial cells
55. Endothelial nitric oxide synthase is regulated by tyrosine phosphorylation and interacts with caveolin-1
56. Nitric oxide mediates mitogenic effect of VEGF on coronary venular endothelium
57. Nitric oxide promotes proliferation and plasminogen activator production by coronary venular endothelium through endogenous
58. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis
59. Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin
60. Podokinesis in endothelial cell migration: Role of nitric oxide
61. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma
62. Suppression of apoptosis by nitric oxide via inhibition of interleukin-1 beta-converting enzyme (ICE)-like and cysteine protease protein (CPP)-32-like proteases
63. Adenoviral transfer of the inducible nitric oxide synthetase gene blocks endothelial cell apoptosis
64. Nitric oxide activates metalloprotease enzymes in articular cartilage
65. Nitric oxide-generating compounds inhibit total protein and collagen synthesis in cultured vascular smooth muscle cells
66. Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats
67. Vascular endothelial cell regulation of extracellular matrix collagen: Role of nitric oxide
68. Nitric oxide in human skin: Current status and future prospects
69. Increased nitric oxide production accompanied by the up-regulation of inducible nitric oxide synthase in vascular endothelium from patients with systemic lupus erythematosus
70. Expression of multiple insoforms of nitric oxide synthase in normal and atherosclerotic vessels
71. Inducible nitric oxide synthase is expressed in granuloma pyogenicum
72. Constitutive endothelial and inducible nitric oxide synthase in inflammatory dermatoses
73. VEGF-A induces expression of eNOS and iNOS in endothelial cells via VEGF receptors-2
74. Inducible nitric oxide and prostacyclin productions are differently controlled by extracellular matrix and cell density in human vascular endothelial cells
75. Peroxynitrite: A two-faced metabolite of nitric oxide